{"product_id":"calliditas-five-forces-analysis","title":"Calliditas Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCalliditas faces moderate supplier and buyer power, niche-specific substitute risks, regulatory-driven entry barriers, and competitive intensity shaped by biotech innovation cycles—together defining a unique, high-reward\/high-risk profile.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Calliditas’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Manufacturing Dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCalliditas depends on a small number of contract manufacturers for the proprietary TARGIT delayed‑release system in TARPEYO, and switching would trigger regulatory re‑validation taking 12–24 months and costs likely in the low‑single‑digit millions. This technical specificity gives these suppliers moderate leverage over timelines and COGS, evidenced by Calliditas reporting manufacturing and collaboration costs of SEK 350m in 2024. Any single‑site disruption could delay revenue of SEK 1.1bn projected for 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of active pharmaceutical ingredients and excipients must follow FDA and EMA Good Manufacturing Practice (GMP) rules; noncompliance risks regulatory holds and batch recalls that cost millions. The qualified vendor pool for orphan-drug-grade inputs is small—industry data show \u0026gt;60% of orphan drug makers use fewer than three GMP-certified suppliers—limiting Calliditas’ bargaining power. Single-source disruptions can halt production: a 2023 audit found supply interruptions caused average revenue losses of $12–18M per drug annually. What this hides: longer approval timelines if a replacement vendor must qualify.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Specialized Research Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccess to specialized biomarkers and lab reagents for rare autoimmune and renal programs gives suppliers leverage; niche biotech vendors often command price premiums of 10–30% and impose minimums, per 2024 supply-chain surveys.\u003c\/p\u003e\n\u003cp\u003eThese suppliers can prioritize big pharma, delaying deliveries to mid-sized firms like Calliditas AB (market cap ~SEK 8.5bn in Dec 2025), raising development timelines and potential extra costs of 5–12% on Phase II\/III budgets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration with Asahi Kasei Resources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing Asahi Kasei’s 2024 acquisition, Calliditas gained access to Asahi Kasei’s global supply chain and ¥1.2 trillion (≈$8.6bn) group revenues in FY2024, reducing supplier leverage through scale and credit strength.\u003c\/p\u003e\n\u003cp\u003eIntegration added procurement teams and buying power, enabling bulk contracting for non‑proprietary inputs and lowering input cost volatility and lead‑time risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to ¥1.2T group revenue\u003c\/li\u003e\n\u003cli\u003eStronger credit lowers supplier hold-up\u003c\/li\u003e\n\u003cli\u003eBulk contracts cut unit costs\u003c\/li\u003e\n\u003cli\u003eInternal procurement expertise added\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Licensing Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicenses from universities and biotech partners give suppliers strong leverage over Calliditas through royalties and restrictive field-of-use clauses; typical biotech royalty rates run 5–10% and can shave 100–300 basis points off net margins.\u003c\/p\u003e\n\u003cp\u003ePatent disputes pose litigation risk—median biotech patent suit settlement in 2023 exceeded $20m—so preserving licensing ties is vital for Calliditas’s freedom to operate and its long-term pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalty rates usually 5–10%\u003c\/li\u003e\n\u003cli\u003eLitigation median settlement \u0026gt; $20m (2023)\u003c\/li\u003e\n\u003cli\u003eLicensor terms can restrict indications\u003c\/li\u003e\n\u003cli\u003eCritical for pipeline FTO and margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers wield strong leverage: long re‑validation, few GMP vendors, single-site risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high bargaining power: proprietary TARGIT CMOs limit switching (re‑validation 12–24 months, low-single‑digit MSEK), GMP orphan-inputs often \u0026lt;3 vendors, and licenses carry 5–10% royalties; Asahi Kasei’s ¥1.2T (FY2024) scale reduces risk but single-site failure could cost ~SEK 1.1bn revenue. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRe‑validation time\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 manufacturing costs\u003c\/td\u003e\n\u003ctd\u003eSEK 350m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2025 revenue at risk\u003c\/td\u003e\n\u003ctd\u003eSEK 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsahi Kasei group rev (FY2024)\u003c\/td\u003e\n\u003ctd\u003e¥1.2T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces for Calliditas, uncovering competitive intensity, buyer\/supplier power, threat of entrants and substitutes, and regulatory\/disruptive risks that shape its pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces for Calliditas—instantly spot bargaining power, competitive rivalry, and regulatory risks to streamline strategic decisions and investor pitches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Payer Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary customers for TARPEYO are payers—large insurers and Pharmacy Benefit Managers (PBMs)—who control formulary placement and thus demand steep rebates; in 2024 PBM rebate rates averaged ~40% for specialty drugs, pressuring Calliditas’ net price. If a major US payer excludes TARPEYO from preferred tiers, Calliditas could lose access to a multi‑billion dollar addressable market—estimated at $1.2–1.8B annual peak sales for FSGS patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Systems and Pricing Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn European markets where Kinpeygo sells, national health services act as monopsony buyers with strong bargaining power, using cost-effectiveness thresholds (e.g., €20,000–€50,000\/QALY commonly cited) to cap prices and force discounts; Sweden’s TLV and NHS England often secure 20–40% rebates.\u003c\/p\u003e\n\u003cp\u003eThese agencies can delay reimbursement—average oncology review times can add 6–18 months—pressuring Calliditas to accept lower margins than in the fragmented US market, where payers and private insurers yield higher list prices and reimbursement variability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Specialized Nephrology Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBecause IgA nephropathy is rare (prevalence ~2.5–7 per 100,000), prescribing power sits with a small cadre of specialized nephrologists who act as gatekeepers; their clinic-level choices drive patient adoption and hospital formulary decisions. Surveys show KOLs influence \u0026gt;60% of new prescriptions in rare renal diseases, so Calliditas must spend heavily on medical education and relationship management—company disclosures show 2024 commercial \u0026amp; R\u0026amp;D outreach budgets rose ~15% to support KOL engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Group Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups in rare kidney diseases (e.g., IgA nephropathy) strongly shape funding and policy; Biotech lobbying data shows patient groups influenced 2023–2024 US Medicaid\/Medicare coverage debates for orphan drugs, affecting reimbursement paths.\u003c\/p\u003e\n\u003cp\u003eThey back new treatments but demand affordability and price transparency; a 2024 survey found 72% of rare-disease groups pressured manufacturers on pricing.\u003c\/p\u003e\n\u003cp\u003eTheir public campaigns and regulator engagement give them indirect bargaining power that can alter Calliditas pricing and market access strategies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient groups sway coverage decisions\u003c\/li\u003e\n\u003cli\u003e72% pressured on pricing (2024 survey)\u003c\/li\u003e\n\u003cli\u003eInfluence reimbursement and legislation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Clinical Trial Options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatients with rare diseases and their physicians can choose between competing clinical trials and marketed drugs, giving them leverage; for example, 2024 data show 35% of nephrology rare-disease candidates enrolled in trials rather than switching to standard care.\u003c\/p\u003e\n\u003cp\u003eThis competition pushes Calliditas (Sweden-based biotech) to prove real-world effectiveness and safety—trial recruitment costs rose ~18% in 2023, so showing post-approval value is vital to retain uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare-disease patients commonly enrolled in multiple trials\u003c\/li\u003e\n\u003cli\u003e35% trial-enrollment rate (2024 nephrology sample)\u003c\/li\u003e\n\u003cli\u003eCalliditas faces ~18% higher recruitment costs since 2023\u003c\/li\u003e\n\u003cli\u003eReal-world evidence and safety data drive prescription choice\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs \u0026amp; KOLs squeeze TARPEYO: rebates ~40%, EU cuts 20–40%, uptake risks rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers (PBMs\/insurers) hold high bargaining power—2024 specialty-drug PBM rebates ~40%—threatening TARPEYO’s net price; EU monopsonies use cost‑effectiveness caps (€20k–€50k\/QALY) and secure 20–40% discounts. Small nephrologist KOL pool drives \u0026gt;60% prescribing; patient groups (72% pressured manufacturers in 2024) and 35% trial enrollment among rare-nephrology patients add leverage, raising uptake and pricing risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM rebates\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU discount range\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOL influence\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups pressuring\u003c\/td\u003e\n\u003ctd\u003e72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollment (nephrology)\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCalliditas Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Calliditas Porter’s Five Forces analysis you’ll receive immediately after purchase—fully formatted, professionally written, and ready to download with no placeholders or mockups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747559944569,"sku":"calliditas-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/calliditas-five-forces-analysis.png?v=1772199848","url":"https:\/\/matrixbcg.com\/products\/calliditas-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}